5 completed, 2 terminated, 1 active not recruiting. 4 Phase 2, 3 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Terminated 2 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Not applicable | 1 | Completed 1 |
Follow (18F)GTP1: new trials by email Literature Review of (18F)GTP1 trials Research Report on (18F)GTP1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis Intra-articular Bevacizumab - Hemophilia, Chronic Synovitis | Not applicable | Completed | Khyber Medical University Peshawar | 18 | 2025-09-09 | 2026-06-25 |
| R21 Roche: 3-Way Tau Tracers in AD [18F]RO-948, 18F-MK6240, 18F-GTP1 - Alzheimer Disease | Phase 1 | Active not recruiting | Washington University School of Medicine | 38 | 2023-02-01 | 2026-05-08 |
| Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease [18F]GTP1, [18F]PI-2620, [18F]MK-6240 - Alzheimer Disease (AD) | Phase 1 | Completed | Genentech, Inc. | 40 | 2020-10-26 | 2023-07-12 |
| Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease Crenezumab, Placebo, [^18F]GTP1 - Alzheimer Disease | Phase 2 | Completed | Hoffmann-La Roche | 114 | 2019-06-10 | 2024-03-15 |
| A Study of Semorinemab in Patients With Moderate Alzheimer's Disease Semorinemab, Placebo, [18F]GTP1 - Alzheimer's Disease | Phase 2 | Completed | Genentech, Inc. | 272 | 2019-01-25 | 2024-09-24 |
| A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease Semorinemab, Placebo, [18F]GTP1 - Alzheimer's Disease | Phase 2 | Terminated | Genentech, Inc. | 457 | 2017-10-04 | 2022-03-16 |
| Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants [18F]GTP1 - Alzheimer's Disease | Phase 1 | Completed | Genentech, Inc. | 72 | 2015-12-23 | 2019-12-23 |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors pertuzumab, erlotinib - Neuroendocrine Tumors, Carcinoid Tumors | Phase 2 | Terminated | Pamela L. Kunz | 4 | 2009-03-01 | 2017-03-03 |
Alzheimer Disease (6) · Adrenal Gland Neoplasms (1) · Brain Diseases (1) · Carcinoid Tumor (1) · Dementia (1) · Hemarthrosis (1) · Hemophilia A (1) · Multiple Endocrine Neoplasia (1) · Neuroblastoma (1) · Neurocognitive Disorders (1) · Neurodegenerative Diseases (1) · Neuroendocrine Tumors (1)
Genentech, Inc. (4) · Hoffmann-La Roche (1) · Khyber Medical University Peshawar (1) · Pamela L. Kunz (1) · Washington University School of Medicine (1)
United States (6) · France (2) · Poland (2) · Spain (2) · Australia (1) · Belgium (1) · Canada (1) · Colombia (1) · Denmark (1) · Germany (1) · Italy (1) · Netherlands (1) · Pakistan (1) · Sweden (1) · United Kingdom (1)
Dr Khalid Khan, MBBS (1) · Dr Kinza Ayaz, MBBS (1) · Dr. Muhammad Tariq Masood Khan, MBBS (1) · Pamela Kunz (1) · Prof. Dr. Yasar M Yousafzai, PhD (1) · Tammie L.S. Benzinger (1)
PMID 38606196, PMID 39350369, PMID 39513754, PMID 40603145, PMID 31834365, PMID 34852837, PMID 35696185, PMID 36641609, PMID 37325545, PMID 37643887
2017 (1)